Skip to content
RDL Network logo
210-Day follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx VELOCITY™ balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions — Jean Fajadet (2002) | RDL Network